MC Healthcare Ventures
Corporate VCActively deployingCambridge · Seed–Series A · 6 people tracked
Find your way into MC Healthcare Ventures
765 people in our graph share verified history with the MC Healthcare Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
The firm invests in seed and early-stage biotechnology companies, primarily located in North America and Europe. It targets companies developing novel therapeutics, platform technologies, diagnostics, and vaccines. Areas of interest include platform technologies such as regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine; novel therapeutics addressing neurodegeneration, immunology, inflammation, and rare disease; and diagnostics for neurodegenerative disorders. As the corporate venture group of Tanabe Pharma Corporation, it offers portfolio companies both large-company resources and small-firm attention. Its team of PhDs supports biotech entrepreneurs in bringing products to market.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from public directories
What they invest in
from 21 of 45 portfolio companiesBiotech ×19Deep Tech ×9Healthtech ×5AI & Machine Learning ×4Medical Devices ×4Digital Health ×2Data & Infrastructure ×1
HQs:United States×12United Kingdom×2Denmark×1Japan×1
Who they back
founder profiles across 10 portfolio companiesFounding team size:solo founder×72 founders×14+ founders×2
Where their founders studiedfrom 10 founders with education data
IMD ×2Stanford University ×2
What their founders studiedfrom 10 founders with field-of-study data
Life Sciences ×8Chemistry ×2
Where their founders worked beforefrom 10 founders with career history
ALBA – Aarhus Life science and Biotech Alliance ×2
Investments · 45 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22021 · 12019 · 12012 · 17 dated
Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.
BiotechHealthtechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in
BoardJean-Francois Formela(Director)in
Co-investorsAtlas VentureNew Enterprise Associates (NEA)AlexandriaQiming Venture Partners USARock Springs CapitalTaiwania Capital+1 more
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Co-investorsBrace PharmaAtlas VentureBoulder VenturesHeartlandRemeditex Ventures
Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
BiotechLondon
Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)
BoardJames Ede-Golightly(Director)Alistair Gray(Director)
Co-investorsForesite CapitalNextech InvestVivo Capital
A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies.
BiotechDeep TechWaltham, US
Errik B. Anderson(Executive Officer, Director)inPiotr Bobrowicz(Executive Officer, Director)inJay Rosanelli(Executive Officer)in
BoardAnthony Sun(Director)Ulrik Nielsen(Director)in
Board seatAlaa Halawa· per SEC Form D · $40M raise · filed Apr 2026
Co-investors82VS8VCAlumni VenturesGermin8 VenturesJIC Venture Growth InvestmentsGaingels+1 more
__Twitter.png)
Innovaccer offers Provider Copilot, an AI assistant that automates clinical documentation, pre-visit prep, medical scribing, and prior authorization workflows for healthcare providers and care teams.
AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US
Abhinav Shashank(Chief Executive Officer and Director of the Issuer)inSandeep Gupta(Chief Operations Officer and Director of the Issuer)inKanav Hasija(Director of the Issuer)inWendy Rubas(Chief Legal and Compliance Officer of the Issuer)inScott Bruckner(Chief Financial Officer of the Issuer)Ankit Maheshwari(Chief Technology Officer of the Issuer)in
Board seatAlaa Halawa· per SEC Form D · filed Oct 2025
Co-investors500 GlobalB Capital GroupB4 CapitalM12 (Microsoft's Venture Fund)OMERS Private Equity Inc.Steadview Capital+5 more
.jpeg){kind=logo}
Blacksmith Medicines discovers and develops small molecule inhibitors of metal-dependent enzymes for oncology and infectious disease applications.
BiotechDeep TechMedical Devices
Zachary Zimmerman(CEO)in
Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells.
AI & Machine LearningBiotechHealthtechVancouver, US
John(Chief Executive Officer)inCharlie(Chief Business Officer)in
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.
BiotechDeep TechMedical DevicesCopenhagen, DK
Simon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)
Co-investorsGilde HealthcareInkefNovo Holdings
Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
BiotechSan Carlos, US
Hugh Y. Rienhoff, Jr., M.D.(Executive Officer, Director)in
BoardMarten Steen(Director)inDennis Henner, Ph.D.(Director)Bryant E. Fong(Director)
Co-investorsClarus Ventures
Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes.
BiotechDeep Tech
Co-investorsAlexandria
Genkyotex was a developer of NOX inhibitor therapeutics, now owned by Calliditas Therapeutics AB.
Biotech
Co-investorsAndera PartnersVesalius Biocapital Partners
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
BiotechCambridge, US
Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)inMichael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)
Co-investorsCycad Group LLCLux CapitalAdvent Life SciencesAlexandriaAuriga PartnersBill & Melinda Gates Foundation+1 more
Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases.
BiotechDeep TechDundee, GB
Satpal Virdee(Founder)
Co-investorsM VenturesDiamond Edge Ventures
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address.
AI & Machine LearningBiotechDeep Tech
Hannah Sore(Founder)in
Co-investorsCambridge Angels groupMartlet CapitalDiamond Edge VenturesO2h VenturesParkwalk AdvisorsWren Capital
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDroia VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health InvestorsAmgen Ventures+7 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesPappas CapitalSV Health InvestorsAbbVie+2 more
SOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins.
BiotechDeep TechMedical DevicesBoston, US
Keizo Koya(Founder and CEO)inAkinori Hishiya(Founder and CSF)in
Co-investorsEisai Innovation, Inc.UTEC
Sonde develops voice-based biomarker technology to detect health conditions early through analysis of speech patterns on everyday devices.
AI & Machine LearningDigital HealthHealthtech
David Liu(Chief Executive Officer)inJames Harper(Chief Strategy Officer)inYogendra Jain(Chief Technology Officer)inErik Larsen(Senior Vice President, Clinical Development & Customer Success)inSanjay Pothen(Chief Financial Officer)Garrett Bussiere(Vice President of Strategic Partnerships)in
Co-investorsEvidity Health CapitalM Ventures
LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.
BiotechDeep Tech
Toru Kankein
Co-investorsTaiho Ventures, LLCUTokyo Innovation Platform Co. Ltd.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ollin Biosciences, Inc.Xilis, Inc.4Ha5Vmy35R7Ok0M0Zp4Bh9Wimfsp4E8Enj3Zaai4Bbwmsildizmboxwmjewk8Enj3Zaai4Bbwmsildizmboxwmjewk B6Lpe Gnpg3 Z8Ex4 Y898G9Equ5Dki1G6Ovoyny5Avrm8Xs1Yq4H9T500O73Tjn462Rnwttpw5Uisfk9VxBlacksmith MedicinesCovagen AGDlg6Blgdw1X23Zd2Fn3Utwj70D3L0KEditForceF StarForgeInflfgxcw49Enfl7Gotzxjfdjjnsv2Intradigm CorporationOwme8X1T7Pdokyw9Tqnehc2Mse3YypPronota NVRigontecSOLASondeSyndexaThrasos TherapeuticsTrimTechYbu1Tjfl79Lsqxfy9Piivuj994EzgyYbu1Tjfl79Lsqxfy9Piivuj994Ezgy Pe225Zd7Sw33Gku8Bpz9Zpq9H43Tpv7Kv5H
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 7
3 IPOs · 4 acquisitionsKorro BioNASDAQ: KRROmiRagen TherapeuticsNASDAQ: VRDNSilence TherapeuticsNASDAQ: SLNCovagen AGacq. by Johnson & JohnsonFerroKin Biosciencesacq. by ShireIntradigm Corporationacq. by Silence TherapeuticsRigontecacq. by Merck
Portfolio news
latest coverage across their companiesSilence Therapeutics · investing.com · Sep 16, 2026
Innovaccer · siliconindia.com · Aug 18, 2026
Ollin Biosciences, Inc. · finsmes.com · Jun 24, 2026
Alloy Therapeutics, Inc. · businesswire.com · Apr 15, 2026
Korro Bio · finance.biggo.com · Apr 15, 2026
Quralis · nasdaqprivatemarket.com · Apr 3, 2026
Capsigen · global.pharmcube.com · Sep 27, 2025
Frequently asked questions
- How many investments has MC Healthcare Ventures made?
- MC Healthcare Ventures has 45 tracked investments, 7 of which have exited, including 4 dated in the last 24 months.
- What stage does MC Healthcare Ventures invest at?
- MC Healthcare Ventures invests at the Seed, Series A stages.
- What sectors does MC Healthcare Ventures focus on?
- MC Healthcare Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is MC Healthcare Ventures located?
- MC Healthcare Ventures is headquartered in Cambridge, US.
- Who does MC Healthcare Ventures co-invest with?
- MC Healthcare Ventures most often shares deals with Andera Partners, Atlas Venture, M Ventures, among 28 tracked co-investors.
Images
Co-investors · 4
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
Cambridge Innovation Capital (CIC) is a UK-based venture capital firm backing entrepreneurs in life sciences and deep tech, leveraging its position in the Cambridge science and technology ecosystem.
Firms observed investing alongside MC Healthcare Ventures, from public investor directories. Shared companies are the overlap with MC Healthcare Ventures's recorded portfolio.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.